Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.

Maha H. A. Hussain

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal

Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.

Alan Haruo Bryce

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

Daniel P. Petrylak

Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≧70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1

Loic Mourey

Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with ¹⁷⁷Lu or ¹¹¹In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).

Scott T. Tagawa

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

Padmanee Sharma

A comparative analysis of patients presenting with optic canal metastasis of prostate cancer.

Neil Kelkar

Disparities in prostate cancer diagnoses in persons experiencing homelessness.

Zachary S Mayo

Social determinants of health (SDOH) and survival among patients with metastatic prostate cancer (mPC): A systematic literature review (SLR).

Stephen J. Freedland

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer.

Maral DerSarkissian

Racial impact (Asian vs. White) on the prognosis of patients with de novo mCSPC: An analysis on LATITUDE, SEER and NCDB.

Xudong Ni

Survival trends in de novo metastatic prostate cancer: SEER and Veterans Affairs comparison.

Martin W. Schoen

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.

Maral DerSarkissian

Genomic profiling between Hispanic Americans (HA) and non-Hispanic (NHW) with advanced prostate cancer: A retrospective analysis of tissue, liquid, and germline testing.

Armaan Dhaliwal

Health disparities in metastatic hormone-sensitive prostate cancer (mHSPC) presentations and outcomes among Hispanic Americans (HA) versus non-Hispanic Whites (NHW).

Aaron Bertolo

Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life.

Shayan Smani

Effect of equal access to care on prostate cancer progression in minority patients.

Ahmad Sami Halwani

Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.

Matthew I. Feng

Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.

Albert Jang

Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center.

Joseph Earl Thomas

Access to care and health care quality metrics in urban versus rural patients (pts) with advanced prostate cancer (aPC).

Haoran Li

<i>CDK12</i> pathogenic mutations in African American and White patients with prostate cancer.

Elisa M. Ledet

Disparities in prostate cancer survival outcomes in Appalachian Kentucky.

Deepali Pandey

Source of funding and enrollment disparity in prostate cancer (PCa) clinical trials.

Irbaz Bin Riaz

Geographic variation in utilization of doublet therapy for metastatic prostate cancer.

Samuel L. Washington

Implementing ¹⁸F-DCFPyL PET in clinical practice: Prescribing patterns and utilization at a large academic center.

Miles Hsu

Prostate cancer screening: Have we tipped the seesaw?

Matthew David Hobbs

The role of the size and number of index lesion in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 4 lesions detected by multiparametric MRI of the prostate.

Mert Kılıç

Patterns of failure after radiotherapy (RT) in patients with prostate cancer restaged with ¹⁸F-DCFPyL PSMA-PET: A regional cohort analysis.

Aruz Mesci

Whole-body diffusion-weighted magnetic resonance imaging to assess bone response in patients with hormone-sensitive metastatic prostate cancer randomly assigned to receive androgen deprivation + enzalutamide ± zoledronic acid.

Alberto Dalla Volta

¹⁸F-PSMA1007 PET/CT in the context of biochemical recurrence of prostate cancer: An economical experience from a Latin American reference center.

Maria Paula Mogollon

Impact of ⁶⁸Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Amelia Altavilla

⁶⁸GaPSMA-11 PET/CT to monitor treatment response in patients with metastatic prostate cancer: The concordance between biochemical response and PSMA response.

Baris Esen

Updated experience on PSMA PET/CT for recurrent prostate cancer in a high-volume Brazilian center.

Dr. Paulo Sergio Lages

Comparative analysis of contemporary and past PSMA PET/CT results for recurrent prostate cancer in a high-volume Brazilian center.

Dr. Paulo Sergio Lages

Effect of body weight on standardized uptake values on ¹⁸F-DCFPyL (PSMA) PET/CT in patients with prostate cancer.

Ashwin Singh Parihar

Leptomeningeal metastases in prostate cancer: A systematic review.

Sharon In Wha Choe

⁶⁸Ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly Study): Preliminary results.

Charlotte Hawkins

Differential treatment response of prostate and metastatic lesions in patients with newly diagnosed metastatic prostate cancer.

Baris Esen

Clinical outcomes after utilization of PSMA PET scans in patients with biochemical recurrent prostate cancer.

Irene Tsung

¹⁸F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging.

Miles Hsu

Prognostic value of C-11 choline PET/CT scan in patients with metastatic castration resistant prostate cancer (m-CRPC) undergoing treatment with radium-223.

Matthew Lee

Factors associated with poor survival outcomes in patients with prostate cancer (PCa) with radiographic disease progression in the setting of low PSA.

Mohamed E. Ahmed

Changes in planned disease management after piflufolastat F¹⁸ PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.

Frederic Pouliot

Ga-68 PSMA-11 impacting prostate cancer management in a real-world setting: A pilot experience using the total-body PET/CT scanner.

Harshad R Kulkarni

The impact of F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states.

Ali Arafa

Real-world treatment patterns and progression-free survival among patients with metastatic castration-resistant prostate cancer: Examining the benefits of sequential androgen receptor pathway inhibitor use.

Jeetvan Patel

Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.

Benjamin H Lowentritt

A study to determine enzalutamide long term safety and efficacy for men with castration-resistant prostate cancer: A multicenter, prospective DELC study.

Koji Hatano

Impact of pre-existing anemia and/or packed red blood cell transfusion prior to Radium-223 administration on oncologic outcomes.

Michael Pierro

Barriers to guideline-concordant use of bone modifying agents for prostate cancer.

Aaron Philip Mitchell

Real-world prostate-specific antigen (PSA) response and disease progression among patients with non-metastatic castration-resistant prostate cancer (nmCRPC) initiated on apalutamide (APA).

Benjamin H Lowentritt

HIDRATE-PRO: A prospective pilot study evaluating a digital behavioral health intervention to improve bladder-filling compliance in patients with prostate cancer receiving radiation.

William Jin

Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Ekamjit Singh Deol

Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).

Gabrielle Robin

Time interval between radium-223 (²²³Ra) therapy and Lutetium-177–prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) treatment and outcomes in the RALU study.

Kambiz Rahbar

Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database.

Rana R. McKay

Survival and hemoglobin A1c in metastatic castrate resistant prostate cancer.

Srinivas Govindan

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Geoffrey T. Gotto

Efficacy of systemic therapy following [¹⁷⁷Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Louise Kathleen Kostos

ECOG score as a barrier for clinical trial eligibility in the patient population with genitourinary cancer: Is it time to adapt this criterion to real-world data?

Limor Gortzak Uzan

Management disparities in metastatic castrate-sensitive prostate cancer (mCSPC).

Nataliya Mar

Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.

Mehmet Asim Bilen

Characterization and survival benefit of drugs approved for metastatic prostate cancer.

David Joseph Benjamin

Association of intermittent vs continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with metastatic prostate cancer.

Alicia K. Morgans

Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer.

Alicia K. Morgans

Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.

Patrick Heckman

First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Lorelei A Mucci

Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.

Terri Conner

Treatment and survival of de novo metastatic prostate cancer in US veterans.

Martin W. Schoen

Physician preferences for nonmetastatic castration-resistant prostate cancer treatments: A discrete choice experiment among men in mainland China.

Yu Fan

Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.

Heba Mohamed

Prognostic role of geriatric assessment (GA) in patients with metastatic prostate cancer (MPCaP) attended in medical oncology.

Regina Girones

Urologic oncology and critical care: What are prognostic factors that correlate with 6-month mortality in patients (pts) with urological tumors referred to intensive care unit (ICU)?

Giulia Kodja Zanetta

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.

Jun Gong

Clinical utility of IDC-P (intraductal carcinoma of the prostate) in the decision making of initial treatment for metastatic hormone-sensitive prostate cancer.

Yushi Naito

Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies.

Sean P. Collins

Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC.

Pedro C. Barata

Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers.

Urbano Anido Herranz

The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).

Pedro C. Barata

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).

Pedro C. Barata

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

Pedro C. Barata

Patient (pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs).

Stephen J. Freedland

Survival in Black and non-Black patients with metastatic prostate cancer.

Nina Cheranda

Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis.

Puneet Dhillon

Main reasons of choice of formulation and route of triptorelin treatment initiated in patients with prostate cancer (PCa): TALISMAN study.

Antoine Thiery-Vuillemin

Investigating documented reasons for withdrawal from clinical trials for patients with advanced prostate cancer (PCa).

Jennifer Lloyd

First UK experience of apalutamide in metastatic and non-metastatic prostate cancer outside of clinical trials.

Prantik Das

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≧75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prost

Richard M. Lee-Ying

Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences.

Praful Ravi

Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC).

Umang Swami

Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline <i>BRCA2</i> mutations (g<i>BRCA2</i>mut) and prostate cancer (PCa): A cost-effectiveness analysis.

Alexie A Carletti

Underutilization of best systemic therapy in patients with metastatic prostate cancer.

Daniel Roadman

Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer.

Annelise Thorn

Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.

Arya Mariam Roy

Real world rates of genetic referrals and germline testing in patients with prostate adenocarcinoma at an academic cancer center in southern New Jersey.

Christopher Ambrogi

A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.

Nely Mercy Diaz Mejia

Socioeconomic vulnerability and the risk of genitourinary cancer mortality among United States counties.

Anum Riaz

Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies.

George Slade Mellgard

Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy.

George Slade Mellgard

Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice.

See-Tong Pang

Patient perceptions regarding the process of obtaining oral prostate cancer medications.

Eric B Schwartz

Simultaneous integrated boost (SIB) stereotactic body radiotherapy (SBRT) for prostate and pelvic nodes in high risk, node positive and oligometastatic prostate cancers: Safety, efficacy and quality of life outcomemeasures.

Trinanjan Basu

Preliminary findings of G8 and G8-modified as screening tools associated with quality of life in elderly patients with prostate, renal or bladder neoplasms in a Brazilian cancer center.

Ingrid Felix Felix Modesto

Effect of cerebral dopamine metabolism genetic polymorphism on patientreported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.

Arjun Gupta

The prognostic value of ECOG performance status on overall survival among patients with metastatic prostate cancer: A systematic review of the literature and meta-analysis.

Jonathan Assayag

Financial toxicity and coping mechanisms in patients with metastatic prostate cancer: A pilot study.

Daniel D Joyce

Leukocyte subtypes and myeloid derived suppressor cells as prognostic markers in metastatic castration resistant prostate cancer treated with cabazitaxel: A satellite study of the CABASTY phase III trial.

Jean-David Heisbourg

Contemporary use of wearable activity monitors in prostate cancer survivors: A scoping review.

Brandon Noorvash

Factors related to men’s experience with prostate cancer germline testing.

Veda N. Giri

Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak

Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

Lisa M. Gudenkauf

Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).

Niven Mehra

A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).

Molly Jameson

Optimising bone health management in advanced prostate cancer: A comparative cohort study.

Anthony Waton

COVID-19 vaccination behavior and outcomes in patients with genitourinary cancer in comparison with other cancer types.

Hyma Vani Polimera

Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART).

Zakaria Chakrani

Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naïve metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.

Soumyajit Roy

Early biochemical outcomes following PSMA-guided approach for biochemical relapse after prostatectomy: PSICHE trial.

Giulio Francolini

Differences in concomitant medication prescribing before and after novel hormonal therapy (NHT) in men with prostate cancer: A population-based study.

Amy Yang

Germline APC (I1307K) mutation and clinical outcomes in prostate cancer.

Minas P. Economides

Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mark N. Stein

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer.

Jose W. Avitia

BMX inhibition and <i>HSD3B1</i>-driven resistance in prostate cancer in the Maverick trial.

Nima Sharifi

Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris

Lutetium-¹⁷⁷ PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: Population-based data with multicenter validation from 2016 to 2020.

Luka Flegar

Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study.

Neal D. Shore

Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.

Arash Rezazadeh

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

Adrish Sen

Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.

Alyssa Liang

The effect of reduced dose of apalutamide on skin adverse events in advanced prostate cancer: A multicenter retrospective study.

Shingo Hatakeyama

Metastasis-directed ablative radiotherapy in castrate-resistant oligometastatic prostate cancer: A retrospective study of 8 high-volume French centers from the COLib (Cercle des Oncologues Libéraux).

Jerome Chamois

Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Niven Mehra

Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Mark N. Stein

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.

Jason J. Luke

Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.

Jonathan David Tward

Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial.

Stephane Oudard

Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).

Lara Pemberton

Intra-individual dose escalation of abiraterone (ABI) according to its plasma exposure in patients (pts) with progressive metastatic castration-resistant prostate cancer (mRCPC): Results of the OPTIMABI trial.

Jerome Alexandre

A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).

Bertrand F. Tombal

Cytoreductive radical prostatectomy (cRP) in the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Axel Heidenreich

P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study.

Daniel Keizman

Comparison of prognostic characteristics between vintage and novel androgen receptor-axis-targeted drug among Japanese patients with nonmetastatic castration-resistant prostate cancer: A multi-institutional study of Japanese Urological Oncology Group (JUO

Shinichi Sakamoto

Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institu

Orazio Caffo

Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium.

Arnold I. Chin

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≧75 years old) with metastatic castration-resistant pros

Vincenzo Gennusa

Real-world outcomes of docetaxel (DOC) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC): First analysis from an Italian multicenter observational study (ECHOS trial).

Orazio Caffo

Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study.

Maria Jose Juan FITA

Comparative outcomes of metastatic prostate cancer (mPC) patients (pts) with DNA damage response gene alterations (DDR-a): A single-center experience.

Khalid Almunaikh

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

Eleni Efstathiou

Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial).

Orazio Caffo

Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alter

Elena Castro

Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Teresa Alonso Gordoa

A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).

Sarah Elizabeth Fenton

Comparative effectiveness of abiraterone and enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort study in a large database of deeply curated EHR realworld data (RWD) from community on

Huijun An

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Rahul Raj Aggarwal

Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.

Russell Kent Pachynski

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).

Praful Ravi

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).

Andrew Leonard Laccetti

Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.

Ronan Flippot

Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.

Michael Philip Sun

Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).

Stuthi Perimbeti

Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for ¹⁷⁷Lu-PSMA therapy in advanced prostate cancer.

Alin Chirindel

An oral androgen receptor RIPTAC for prostate cancer.

Kanak Raina

Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.

Can Aydogdu

Therapeutic potential of plant-derived nanovesicles for neuroendocrine prostate cancer.

Sharanjot Saini

Physician-driven artificial intelligence enabled planning for intraprostatic dose escalation in under ten minutes.

Kareem Rayn

Transdermal square-wave testosterone therapy: A pilot trial in metastatic castration-resistant prostate cancer.

Nellowe Candelario

Effect of early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting on cancer-specific survival in metastatic castrate-resistant prostate cancer.

Kelly Lehner

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.

Mark Christopher Markowski

Early outcomes from lutetium Lu-177 vipivotide tetraxetan treatment in patients selected for therapy with piflufolastat F-18 PET imaging.

Thomas Pence Boike

High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting.

Kelly Lehner

A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).

Irbaz Bin Riaz

The effect of statin use on survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted therapies (ART).

George Slade Mellgard

Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.

Syed Arsalan Ahmed Naqvi

Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC).

Patrick Glen Pilié

Titration as an effective strategy to reduce apalutamide induced skin rash: A multi-institutional real-world experience.

Zhixian Yu

Prognostic value of pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.

Zhipeng Wang

Prognostic impact of circulating tumor cells in oligometastatic hormone-sensitive prostate cancer following metastasis-directed therapy.

Soha Bazyar

Predictive and prognostic potential of pretreatment ⁶⁸Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer (mCRPC).

Majid Assadi

Association of whole blood mRNA expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).

Akeem Ronell Lewis

Role of adenomatous polyposis coli (APC) gene in SPOP-mutant prostate cancer and clinical outcomes.

Shamis Khan

Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy.

David Dewei Yang

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis

Impact of vaccination against SARS-CoV-2 on the risk of hospital admission and death among infected patients with urologic cancers: A population-based study in northern Italy.

Lucia Fratino

Development of machine learning–powered models for prostate cancer HRD prediction.

Michael Nercessian

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Elias Chandran

Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).

Rahul Raj Aggarwal

Prognostic biomarkers and clinical outcomes in neuroendocrine prostate cancer (NEPC).

Richard Gagnon

Healthy lifestyle, Agent Orange exposure, and inherited PCa risk: An analysis of the Million Veteran Program.

Meghana Pagadala

RIPK2 as a prognostic biomarker and predictor of aggressive prostate cancer.

Mustafa Hammudi

The prevalence and clinical significance of HER2 overexpression in prostate adenocarcinoma.

Fayez Estephan

The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer.

Nobuaki Matsubara

Impact of somatic DNA repair mutations on bone-related efficacy endpoints in patients with metastatic castration-resistant prostate cancer (mCRPC): A retrospective analysis.

Maria Concetta Cursano

Distinct genomic features and evolutionary relationships between concurrent intraductal carcinoma and adenocarcinoma of the prostate.

Sha Zhu

Effect of neuroendocrine differentiation on therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.

Nanwei Xu

Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.

William Gesztes

Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.

Edmond Michael Kwan

Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.

Anna S. Trigos

Spectrum and implications of activating <i>BRAF</i> alterations in advanced prostate cancer (aPC).

Alex Chehrazi-Raffle

Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

Alice Bernard-Tessier

Role of epigenetic regulator <i>KMT2C</i> mutation detected by liquid biopsy in survival in patients with prostate cancer.

Nanwei Xu

Inherited mutations in DNA damage gene repair (gDDR) in Italian men with metastatic prostate cancer.

Ugo De Giorgi

Erythroblast transformation-specific transcription factor fusions in prostate cancer.

Michelle Barbi de Moura

Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers.

Jones T. Nauseef

Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT.

Ray Manneh Kopp

Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer.

Samir Zaidi

Using microfluidic models to evaluate whether monocyte preconditioning plays a role in tumor-associated macrophage mediated resistance to hormone therapy in men with prostate cancer.

David Kosoff

Clinical implications of <i>Wnt</i> signaling alterations in patients (pts) with advanced prostate cancer (aPC).

Amanda Broderick

Characterization of ctDNA findings at the end of life in patients with prostate cancer.

Kanika Gupta

Association of obesity with tumor differential gene expression and gene set enrichment pathways in advanced prostate adenocarcinoma (PCa).

Vinay Mathew Thomas

Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping.

Cameron Herberts

Correlation of age and the tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa).

Kamal Kant Kant Sahu

Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to intensified androgen deprivation therapy (i-ADT).

Vinay Mathew Thomas

Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer.

Nicolas Sayegh

Development and validation of a gene expression signature based on <i>RB1</i>, PTEN, and <i>TP53</i> in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Oscar Reig Torras

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer.

Manish Kohli

Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer.

Philip Sutera

Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).

Daniel S Childs

Clinical and genomic factors associated with tumor mutational burden (TMB) in prostate cancer.

Helen Y Hougen

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Adam B Weiner

Biology and usefulness of [-2]proPSA as a prognostic marker in CRPC patients.

Yoshiyuki Miyazawa

Evaluation of ctDNA in patients treated with lutetium-177-PSMA-617.

Sree M Lanka

Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM).

Nishita Tripathi

Clinical and molecular features of <i>ATM</i> and <i>BRCA2</i> mutations in metastatic prostate cancer.

Xiaolei Shi

Analysis of <i>TP53</i> gain of function mutations in metastatic castration-resistant prostate cancer.

Patrick L Sweeney

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Amy K Taylor

Genomic alterations in patients with prostate cancer with liver metastases.

Crystal Casado

Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.

Christopher Sweeney

Evaluation of the aggressive variant prostate cancer molecular profile (AVPCm) in CLIA environments.

Paul Vincent Viscuse

Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer.

Ethan Barnett

Development and validation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection.

Irvin Mark Modlin

Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in <i>BRCA2</i>.

Minqi Huang

Long-term taxane exposure and transdifferentiation of prostate cancer in vitro.

Gunhild Von Amsberg

Natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Ahmed Zedan

Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.

Santosh Gupta

Pathogenic <i>BRAF</i> mutations in prostate cancer: Frequency and distribution.

Elisa M. Ledet

Single and multi-hit <i>PIK3CA</i> short variant (SV) genomic alterations (GA) in clinically advanced prostate cancer (CAPC): A genomic landscape study.

Carla Miguel

Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies.

Tori Seasor

Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database.

John Shen

Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.

Sachdev P. Thomas

The impact of genomic biomarkers on a validated clinical risk prediction model for upgrading/upstaging among men with low-risk prostate cancer.

Avery Braun

Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.

Liat Hammer

Gender disparities in the National Institutes of Health funding for genitourinary oncology.

Muhammad Zain Farooq

Association of exposure of Camp Lejeune contaminated water and prostate cancer outcomes.

Leah N. Deshler

A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.

Sarah Elizabeth Fenton

Oncologist-driven development of an electronic health record (EHR) clinical data visualization tool for prostate cancer.

Teja Ganta

Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.

Manish Kohli

Survival patterns based on site-specific visceral metastasis in patients with metastatic prostate cancer: Are outcomes of visceral metastases the same?

Mohamed E. Ahmed

Perioperative outcomes of radical prostatectomy for advanced stage, node positive, and metastatic prostate cancer.

Rishabh Kumar Simhal

Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

Shahneen Sandhu

Survival outcomes of metastatic castration-resistant prostate cancer in Brazil (LACOG 1818).

Fernando Cotait Maluf

A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio).

Andrew Warren Hahn

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.

Channing Judith Paller

Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial.

Zaker Hamid Rana

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial.

Pedro H Isaacsson Velho

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao

LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [¹⁷⁷Lu] Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Louise Kathleen Kostos

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal

AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [¹⁷⁷Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Louise Kathleen Kostos

VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [¹⁶¹Tb]Tb-PSMA-I&T.

James Patrick Buteau

A multi-center, open-label, randomized dose expansion study of PF- 06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mariona Calvo

NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).

Bridget F. Koontz

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

William Kevin Kelly

A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.

Francisco Gonzalez

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

Simon J. Crabb

A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

Jones T. Nauseef

CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).

Matthew Raymond Smith

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak

A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).

Vivek Narayan

A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

Alan Haruo Bryce

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.

Jonathan Alexander Chatzkel

ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Umang Swami

AtezoCab: A phase II study of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with non-measurable disease (NMD).

Umang Swami

Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Arun Azad

Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).

Neal D. Shore

PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

Nicholas John Van As

Patient-level data meta-analysis of a multi-modal artificial intelligence (MMAI) prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG phase III randomized trials.

Daniel Eidelberg Spratt

Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials.

Abdenour Nabid

FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Paul L. Nguyen

10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016).

Isabel Syndikus

Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).

Atsunori Yorozu

The profile study: Prostate cancer screening in men of Black African and African Caribbean ancestry—Early results.

Netty Kinsella

Associations between patient sociodemographic factors and non-treatment for localized prostate cancer.

Madison Novosel

Increased prostate volume on transrectal ultrasound and magnetic resonance imaging are potential risk factors for acute urinary retention following transperineal prostate biopsy.

Maxwell Sandberg

Patterns of failure with ¹⁸F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.

Samantha S. Sigurdson

Ability of STAR-CAP staging system to prognosticate risk of subsequent therapies after initial treatment of M0 prostate cancer.

Daeun Sung

Prediction of significant prostate cancer in equivocal MRI lesions: A high-volume international multicenter study.

August Sigle

Geometry of hydrogel rectal spacer placement and risk of MRI-identified rectal wall infiltration.

Jonathan W. Lischalk

Radiographic-pathologic concordance in the workup of locally radiorecurrent prostate cancer.

Luca Faustino Valle

Is transrectal ultrasound or magnetic resonance imaging better at estimating prostatic volume for patients with prostate cancer?

Maxwell Sandberg

Detection of true positive M1 lesions by ¹⁸F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.

Bridget F. Koontz

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.

Samuel Tremblay

Development and validation of a novel radiomic model for predicting posttreatment prostate cancer recurrence.

Linda My Huynh

Positron emission tomography of patients with confirmed prostate cancer using ⁶⁴Cu-SAR-bisPSMA.

Louise Emmett

BPH-related false positive of ⁶⁸Ga-PSMA PET/CT in the diagnosis of prostate cancer: The Achilles heel of biopsy-free radical prostatectomy?

Wei Tang

Comparison of transperineal and transrectal biopsy approaches to detect clinically significant prostate cancer in patients undergoing MRI fusion prostate biopsy: A lesion level analysis.

Andrew Wood

Analysis of false-positive biopsy results of PIRADS 4 lesions in multiparametric magnetic resonance imaging of the prostate: Experience from a single nonacademic center using cognitive fusion.

Augusto C. A. Mota

Persistent need for systematic biopsy for those on active surveillance for early-stage prostate cancer.

Mary Fakunle

Impact of MRI and targeted biopsy on oncological outcomes of prostate cancer after treatment.

Neha Debnath

The impact of focal therapy tumor boards, including prostate magnetic resonance imaging overreads, in refining the selection candidacy for focal therapy patients: A prospective study.

Tarik Benidir

The natural progression of patients with an IsoPSA value and its predictive ability of clinically significant prostate cancer on biopsy.

Nour Abdallah

De novo prostate cancer in renal transplant recipients: A single-center study.

Arthi Sridhar

A national questionnaire survey of Japanese urologists on the treatment perspective for elderly patients with prostate cancer.

Takuma Kato

Awareness of genetic risk for prostate cancer (PCa) inmen from families with germline mutations in DNA-repair genes.

Massimo Lazzeri

Patient opinions on controversies: In regard to low-risk prostate cancer, is Gleason 6 the old Gleason 5?

Howard Wolinsky

Real-world clinical outcomes of patients with localized prostate cancer (LPC) treated with external beam radiation therapy (EBRT).

Lawrence Ivan Karsh

Real-world use of darolutamide, enzalutamide, and apalutamide for nonmetastatic castration-resistant prostate cancer (DEAR).

Daniel J. Georg

Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.

Michael Leapman

“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.

Ryan Sutherland

Real world prospective evaluation of clinical outcomes in patients with nonmetastatic castrate resistant prostate cancer treated with darolutamide.

Amarnath Challapalli

Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.

Shunsuke Kamijo

Multi-institutional prostate cancer unit of Padova: Review of activity and performance indicators of the first 18 months after ISO9001 certification.

Marco Maruzzo

Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.

Tony Felefly

Effect of prostate brachytherapy case volume in the community setting on oncologic outcomes.

Kevin Chang

Validation of baseline health-related quality of life as prognostic indicator for survival outcome in men with intermediate risk prostate cancer undergoing radical prostatectomy.

Thilo Westhofen

Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials.

Eduardo Felicio Campos

Impact of psychological distress on emergency room utilization and mortality among prostate cancer survivors.

Changchuan Jiang

Urinary proteome as a prognostic factor in the deterioration of the quality of life of patients with localized prostate cancer during radiotherapy: Radiotoxicity Bladder Biomarkers (RABBIO) prospective trial.

Carole Helissey

Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.

Udit Singhal

Sexual function after primary external beam radiation therapy (EBRT) for prostate cancer in a large cohort of men with long-term follow-up.

Domenique Escobar

Longitudinal analysis of persistent stress urinary incontinence after radical prostatectomy and time to definitive surgical treatment: Data from CaPSURE.

Avery Braun

Major adverse cardiovascular events after androgen deprivation therapy in patients with prostate cancer with hypercholesterolemia.

Przemyslaw Twardowski

Two-fraction stereotactic MRI-guided ablative radiotherapy with simultaneous boost to dominant intraprostatic lesion: Results from the 2SMART phase 2 trial.

Wee Loon Ong

Predictor of adverse pathology in patients who underwent deferred radical prostatectomy following active surveillance: Results from multi-institutional prospective observational cohort in the PRIAS-JAPAN.

Yoichiro Tohi

Major adverse cardiovascular event risk following androgen deprivation therapy initiation by personal history of cardiovascular events.

Andrew Lee

Safety and quality of life analyses of apalutamide plus active surveillance vs active surveillance alone for low, intermediate risk prostate cancer.

Gwenaelle Gravis

Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).

Alan Dal Pra

Trends in the use of local intervention and its impact on oncological outcomes for metastatic castration-sensitive prostate cancer: A multicenter retrospective study.

Shingo Hatakeyama

Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy in recurrent prostate cancer.

Constantinos Zamboglou

Planned interim analysis of perioperative safety of fluzoparib combined with abiraterone in the neoadjuvant treatment of locoregional high-risk prostate cancer: Results from multicenter, phase 2 FAST-PC trial.

Yao Zhu

Oncological outcomes with wide resection in robot-assisted radical prostatectomy as primary treatment for very high-risk prostate cancer.

Noriyoshi Miura

Cost-effectiveness of abiraterone acetate for high-risk nnon-metastatic prostate cancer.

Nataniel Hernan Lester-Coll

Length and Gleason pattern at positive surgical margin after radical prostatectomy to assess risk of postoperative recurrence in localized prostate cancer.

Masashi Kato

Single-arm phase 2 clinical trial evaluating neoadjuvant abiraterone and gonadotrophin-releasing hormone agonist in high-risk localised prostate carcinoma: CTRIAL-IE (ICORG) 13-23.

Geraldine Murphy

5-Year result of single-institute cohort study in single-fraction HDR monotherapy for localised prostate cancer.

Imtiaz Ahmed

Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers

Hsin-pei (Spencer) Hu

A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR).

Kamal Kant Kant Sahu

Stereotactic reirradiation for local prostate cancer recurrence: Monoinstitutional experience of 108 patients.

Manon Baty

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual patient data meta-analysis from the MARCAP Consortium.

Wee Loon Ong

Effect of undetectable PSA following SRT for biochemical recurrence on BPFS, FFM, and OS.

Sophia Scharl

Partial gland ablation outcomes for localized prostate cancer in patients with MRI-visible and MRI-invisible lesions.

Alec Zhu

Short term pathologic outcomes and biochemical recurrence rates of single port transvesical retzius-sparing radical prostatectomy as compared to multiport radical prostatectomy

Tarik Benidir

HDR brachytherapy and radiotherapy as salvage treatment for macroscopic recurrence in the prostate bed after radical prostatectomy

Benjamin Guix

Effect of neoadjuvant stereotactic body radiation therapy (SBRT) on the immune microenvironment of high-risk localized prostate cancer in paired transcriptomic analysis of pretreatment biopsy and irradiated prostatectomy specimens.

Ariel E. E. Marciscano

Societal benefits of surrogate outcomes to support reimbursement decisions: The case of prostate cancer.

Rafael de Feria Cardet

Germline DNA damage response (DDR) mutations in an East Asian (EA) cohort with prostate cancer (PCa).

Joanne Y.H. Lua

Development and clinical validation of a novel biopsy-based six-gene signature to accurately risk-stratify men with early-stage prostate cancer to aid treatment decision making.

Agnieszka Krzyzanowska

Comparative transcriptomic analysis of DNA-damage response and androgen receptor pathway activity between biopsy and radical prostatectomy specimens before and after pre-operative real-time MRI-guided stereotactic body radiotherapy.

Himanshu Nagar

Geographic variation of decipher genomic classifier in patients with early prostate cancer.

Daniel Keizman

Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study.

Marijo Bilusic

Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.

Elaine T. Lam

Detection of intraductal carcinoma of the prostate (IDCP) cases focusing on high-grade prostatic intraepithelial neoplasia (PIN) findings regarding invasive carcinoma of the prostate.

Ryuta Watanabe

Characterization of lymph node metastases in prostate cancer.

Josh Gottlieb

Limited relevance of the “very low risk” prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort.

Kevin Shee

The difference in serum testosterone recovery between Gn-RH Antagonist and LH-RH agonist among patients with prostate cancer treated with radiation therapy.

Akinori Takei

Germline testing for men with prostate cancer: Need to broaden the indications in Europe?

Elena Trevisi

Polo-like kinase-1 as a potential prognostic marker of prostate cancer utilizing ORIEN data.

Snigdha Nutalapati

Prospective validation of single nucleotide polymorphisms as predictors of gastrointestinal, genitourinary, and sexual toxicities following radiation therapy for prostate cancer.

Sophia C. Kamran

Prediction of early prostate cancer recurrence using a liquid biopsy approach.

Kambiz Rahbar

A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer.

Cayce Ben Nawaf

Use of IsoPSA with prostate MRI PIRADS score in biopsy decision making in patients with elevated PSA.

Tarik Benidir

Diagnosis of prostate cancer using cell-free DNA methylation profiles from expressed prostatic secretions.

Wenhao Shen

Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).

Anna Couvillon

Biochemical recurrence (BCR) surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate (BCRSCRAP): A meta-analysis from MARCAP Consortium.

Soumyajit Roy

Associations between plant-based diets and risk of disease progression in men with prostate cancer.

Vivian N Liu

Long-term rates of biochemical recurrence after primary external beam radiation therapy (EBRT) for prostate cancer.

Domenique Escobar

The landscape of prostate cancer research in Canada.

Mike Fraser

National population-based survival estimates after definitive radiation therapy for prostate cancer.

Daniel Herr

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.

Tamim Niazi

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [⁶⁸Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.

James Patrick Buteau

A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX.

Daniel Eidelberg Spratt

Randomized trial of five or two MRI-guided adaptive radiotherapy treatments for prostate cancer (FORT).

Ariel E. E. Marciscano

Randomized trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks vs. 2 weeks (SHORTER).

Ariel E. E. Marciscano

Neo-adjuvant PARP inhibition prior to prostatectomy: A phase II biomarkerdriven trial for men with high-risk, localized prostate cancer and alterations in DNA repair genes.

Marc Dall’era

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Neha Vapiwala

Radiation therapy and irreversible electroporation for intermediate risk prostate cancer (RTIRE).

Timothy D McClure

Angelica herbal supplement AGN-CognI.Q acute dose safety and pharmacokinetics (PK) dose-response in patients with prostate cancer (PK Dose Trial).

Monika Joshi

The CONFIDENT-P trial: Clinical implementation of artificial intelligence assistance in prostate cancer pathology.

Rachel Flach

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.

Karan Jatwani

Clinical applications of urine- and blood-based genome wide copy number study from 1,000 patients with bladder and prostate cancer

Chao Dai